Unit BLOOD DISEASES
- Course
- Medical, veterinary and forensic biotechnological sciences
- Study-unit Code
- A001773
- Curriculum
- Medico
- Teacher
- Enrico Tiacci
- Teachers
-
- Enrico Tiacci
- Roberta La Starza (Codocenza)
- Hours
- 7 ore - Enrico Tiacci
- 45 ore (Codocenza) - Roberta La Starza
- CFU
- 6
- Course Regulation
- Coorte 2022
- Offered
- 2023/24
- Learning activities
- Affine/integrativa
- Area
- Attività formative affini o integrative
- Academic discipline
- MED/15
- Type of study-unit
- Obbligatorio (Required)
- Type of learning activities
- Attività formativa monodisciplinare
- Language of instruction
- English
- Contents
- Hematopoiesis (erythropoiesis, granulocytopoiesis, monocytopoiesis, plateletopoiesis, lymphocytopoiesis).
Clonal hematopoiesis
Characteristics of blood cells. Hematopoietic and leukemic stem cell. Mechanisms of gene regulation (gene mutations, chromosomal rearrangements, mutations in non-coding sequences with formation of new enhancers, gene silencing, methylation, role of telomeric and centromeric regions, oncogenes, tumor suppressors
Leukemogenesis. Clonal age-related hematopoiesis. Molecular bases and molecular mechanisms of: Chronic myeloproliferative syndromes
Myelodysplastic syndromes
Acute leukemia (lymphoid and myeloid)
Chronic lymphocytic leukemia; non-Hodgkin's lymphomas (high and low degree; at B- and T- cell), Cellular plasma discrasias
Hereditary hematological malignancies, congenital syndromes with an increase risk of leukemia, predisposing abnormalities - Reference texts
- Corso di malattie del sangue e degli organi emolinfopoietici (S.Tura, Esculapio Ed)
Introduzione alla Medicina Molecolare (D Ross, Springer Biomed) - Educational objectives
- At the end of the course the student will have to know the main elements of genetics, and epigenetics, that underlie the pathogenesis and / or progression of onco-hematological diseases
- Prerequisites
- Knowledge of the main causes of the disease and the related etiopathogenetic mechanisms. Basic physiopathological mechanisms of the main systems and systems. Elements of pathological anatomy, histological and cytological examinations
- Teaching methods
- Lessons
excercises - Other information
- Evaluation of the internship is carried out in progress and during the course of the student's practical activities
- Learning verification modality
- Written exam with 2 open descriptive questions (10-15 lines available). The candidate has 30 minutes for these questions.
- Extended program
- Hematopoiesis, stem cells, myeloid lineage differentiation and lymphonodes, organs of hematopoiesis (bone marrow, liver, spleen, yolk sac) lymphatic system; Blood: corpuscular elements, plasma.
Clonal hematopoiesis and involved genes
Molecular-cytogenetic markers for the genetic diagnosis of Acute leukemias: LAM, LAL B cells, LAL T cells: clinical and diagnostic tests; chronic myeloproliferative diseases: chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, chronic eosinophilia leukemia; Myeloid and lymphoid neoplasms with tyrosine kinase involvement FGFR1, PDGFRA, PDGFRB; Chronic lymphatic leukemia, hairy cell leukemia, indolent and aggressive, B-cell and T-cell non-Hodgkin's lymphomas; Monoclonal gammopathies: MGUS, multiple-smoldering and symptomatic myeloma, solitary plasmacytoma of bone; medullary aplasia; Myelodysplastic syndromes
For each nosological entity the classification aspects that are based on internationally recognized criteria (WHO 2017) will be addressed, in particular I will focus on the bio-molecular aspects of diseases. The physiological and pathological functional aspects of oncogenes and suppressors involved in the pathogenesis and / or progression of the disease will be addressed. The mechanisms of deregulation of cellular functions (proliferation, self-maintenance, survival and differentiation) which underlie the leukemic transformation will also be discussed.
A focus will be made on the main signal transduction pathways that are deregulated in the main hematological neoplastic diseases and that represent potential targets of molecular therapy. - Obiettivi Agenda 2030 per lo sviluppo sostenibile
- 3 - Health and welfare